The U.S. FDA approved PegIntron (peginterferon alpha-2b) in January 2001. According to official statistics, by the end of 2002, the number of patients treated with PegIntron worldwide had reached 300,000, including 150,000 patients in the United States, which fully proved the efficacy and safety of PegIntron.

Peginterferon alpha-2b is a long-acting interferon that binds to receptors on the cell surface. , exerting a variety of biological effects, including anti-viral, immune regulation, etc.

It has a certain effect in the treatment of chronic hepatitis C. It can help inhibit the replication of hepatitis C virus, reduce liver inflammation, and improve liver function.